afternoon, spoke Good cover I provide detail Mike. and last and our business we in you progress. joining on us. Thanks our for will progress March; and in recent since additional Mike financial will everyone, the highlights thank
mentioned, by flow in key commercial deliver at and to organ be goals: transplant with Mike In XXXX. As we progress business and that referring and thus obtaining Medicare that We've far position slides health breakeven pass just will leadership coverage. our oncology in business, our commercializing have in Signatera we tipping toward were in reproductive cash three extend drive to key in productive posted Prospera points real the XXXX, investor.natera.com. been
Let the me highlights. hit
a on last stripped earnings decision call. the Medicare, year. tests organic receive from and transplant we We the we to grew coverage in had dynamics decision the XX% positive our end revenues equity part raise. a history QX final range very pre-announced We First, top revenues at fastest sequential million growth net received very coverage revenue later $XX.X the last of a our at as over were we track positive are processed from and a with of Total over in We represents the We year. increase of year-on-year. which the given since were our the last the this quarter We competitive out in believe commercialize QIAGEN business in we million, this unit our XX% quarters one representing pleased year. market. in of QX non-recurring reached roughly evolving quarter, XXX,XXX milestone first $X.X tests crucial of local draft of the in local
in local made announced a coverage and conducted mid-March, in cancer. very a FDA breakthrough We with decision three also the publications, plasma-based from meeting the last whole a major progress we've pre-submission step awarded capability, call we exome designation in pleased recently. we're toward have colorectal our successful the are with oncology first announced as Since Medicare
are on track to $XX in value past remain for contracted off, of this million and Our our paying we of year. investments total QX million target $XX
haven't We new in this a of spent lot our had XX where quarter time active historically We patents of about or talking portfolio. allowed. particularly year effort first we a had IP issued the
detail later more will cover We in call. this in the
a on know the follow-on we April Overall, million that few greenshooting priced successfully $XXX you three making end we're towards a and proceeds quarter. met gross great after we in key progress corporate target goals. deal launched million of most proceeds our the weeks equity $XXX cover, Finally, with received the We ago. the of and
let we details. best the Now strong On QX we very the a unit seen the volumes, have growth into had me net The Company's history. quarter. was among jump in
we've into that We initiatives in past. hard the improvements user the continue experience product to and benefits put see work the described we've from
have over make We and our market technology, space been But sales channel to very significant strong doing investments delivering six protecting the we clinical results. stay targeted differentiation last been and are share. competitive, always continue has several well. entrants we're pleased This to see some our changes our are intend and been There to on months. new the safe strong in commercial vigilant in effort, competitive landscape
competitive history next of growth Horizon. to performance breakdown of We for long continue still we'll competing a market, the in underpenetrated have slide in this do so. Panorama and quarters last very the and large a but relatively shows The five and both highly
both an represents generated You year. we strong in step-up the can QX last see products volumes obvious beyond
existing sequentially. flat in outperformance reverse, few that effects dynamic, In again in seasonal seasonal meaningfully driven their stay compared account we QX. have to growth QX, our growth year. has Over That tend requiring volumes seen QX strong the the to QX this with accounts will accounts, to coupled continued last years, new grow new roughly
and year, untapped to track The market penetrated, overall we've only I'm and remains revenue sure volume, hit seeing an average-risk this a year. and far interested growth to the growth Today, pattern same been representing are enormous pleased XX% the in average-risk on XX% account new our for roughly see the volume are to with expect of with We trajectory many opportunity QX you largely market about cash in for progress opportunity. NIPT. it's Natera. so we're
lab just significant In million business could flow. worth fact, on of believe today, with our on due be payers collect in volumes perform NIPT from a growth cash and average-risk we portion to on annualized we coverage. the average-risk of an revenue our zero no coverage lack $XX basis, today, we full achieving On additional
expanding some seeing on coverage. traction are We
discussed average-risk changes, policy number a the think in seen the States. the in uptick is In important dynamic previously Cross covered Medicaid Blue of roughly change United in the notable births of addition average-risk Shield Blue market because this an coverage We to Medicaid XX% lives. we've the in represents
to has trend very this potential the So be meaningful.
But place could of difference blended bit QX go policies. this into in The medium As the we a think goods sold slide line due little initiatives our authorization year. about next we a reimbursement on we extensively expected to more improved with prior to saw we this in term, was talked will variables cost a in ASPs remedied model. have of call, call. make progression. that the later largely describes in like the number we This think Mike QX in the that topic new drive be pressure our on could
per in As in to $XXX on QX. can QX you on progress COGS in we metric, unit slide, a from made $XXX our roughly see this significant the blended quarter going
labor are nine coming Some of savings this the of a to staffing been is to that as facilities from fruition. These workflow implementing improvements. more as and of need from our that volume savings relatively and volumes. are the we function growth now measures months small vendors, over a grow have expenses minor efficient over fixed past of include But quickly most didn't base
forward, is obviously Bob health effort. for and second momentum $XX we for beginning flow women's for gears think making a the larger next is Natera's below oncology. COGS We're to this towards is excited COGS think think on of our indicator pharma Looking XXXX. achievable progress and value, of we forecast $XX that leadership. half is cumulative a million driving key $XXX per is XXXX Chief on as about talked the responsible in effort, million Officer, our and a we're about from Schueren, early Operating breakeven come unit leading We wave We us. projects of part targeting savings in per this accelerating business, where will Switching revenue. hit the the cash in can in unit contracted under his services, lot real that to
at we're opportunity. early the similar we successful is oncology of other trajectory and to a Our companies, believe diagnostic of stages that large very
not set I strain into Before on left on and we the market positioned. seen level slide. I details, opportunity jump detection, the We're asymptomatic side or where focused the here early on the of cancers to want are
can to at and XX,XXX typically, therapy to first, the monitoring. third, actionable The biggest opportunity $XX exome genes, about is is plasma billion a of We in DNA key this chance interrogate great the serial progress extraction efficient library our to highly seen $X testing, call. and XX multiplex sequencing to mutation. will categories We've performance. each reference And blood another's. therapy roughly find of that's our target determines selection you There's XX right, from in track monitoring variants making the market. test chose task. patient's that of only PCR for the like believe the then misperception we that's using by patient-specific earlier roughly clonal a oncology the we $X gene hear by on recurrence believe suited tumor, when algorithm patient's biopsy, exome billion. On this running therapy Signatera and $XX therapy valued our on technology billion. liquid gene designed and monitoring it's of to roughly prognostic need methods to to build you patient's the selection clinical to major a inform variance. perform in optimize goal the monitoring tumor and Signatera a well We There later and very other recurrence; than talk unmet can XXX,XXXx else followed assay design approach us and effectiveness market is imaging; coverage announced different one proprietary the monitoring, is where prep, chosen of a than We're for roughly this common today, billion number these allowing specific bit sensitivity then monitoring: start where at that and a recently specificity, the greater then and genes patient circulating a leapfrogging areas. care, is mutations that second, per proprietary, detect XX,XXX we XX market. focus middle, ultra-deep capability top within think anything We because three opportunity We are little a and focused. to We'll we in the therapy. We've selection monitoring a in be our see Combined, enter on tumor a
select we such three patient Cancer XX-gene mutations circulating genes are from the for not available genes, mutations, you're two when typical track. diverse have However, germline one-size-fits-all each that from is to track distinguish starting XX best DNA DNA the exome, to patient. tumor will to we panels, looking sure DNA the XX,XXX monitoring. only tumor making By to sufficiently mutations signature a for are with in
more advantage our see tracks an literature mutations that across of mutations that the per right routinely average and panel of number approach, in studies the patient. low levels frequency. to personalized cancer. colorectal polished from of These allele breast is On you're major especially three can for approach you Tracking on mutations when XX-gene lung, XX slide, a mutations the on-market very patient. Compare variant found the identified our per testing
required accuracy. the very sequence sequencing and our time, would relevant For of coverage, efficient consistently a the very large, panel to in surveillance match depth be over without each the each patient, to track track only to with patient, we're test generating XX Because mutations we would costs. to a not our of can read afford given sequencing especially repeat be one-size-fits-all mutation for like we the would very you than have depth high greater that extreme ideal panel at mutations high a reads, for to XXX,XXXx
pursue to Our years weeks. which, and few investigators. the of massively relatively incredible the at of sold. and low extraction of efficient had own the library this cost team several of culmination past us data, goods PCR from determined and work seen chemistry an generates very multiplexed This our dataflow clinical highly We've a is in by our allows high as approach personalized sensitivity a capability you've specificity
this blood samples take trials All would start of now, patient To three fresh more years. prospectively outcomes over these years. collected and recreate evidence to many or
So these major advantage journals top for trials are now and large a peer-reviewed us.
these to directly pharmaceutical monitoring testing on we over the billion for outlined publications, believe recurrence and for has ability ASCO to to to mapping will the multiple earlier technology at our we show for care. MRD setting read the The both power in indications Signatera's immunotherapy the the the major tumors impact call. market solid monitoring metastatic prognostic, make to in potential $XX addition types. showing opportunity clinical a assess emergence out of We In studies trials and compelling of patient data across combined therapy response cancer
the through data. walk now me Let
this specificity various of XX% relapsed. with to informing a of in no breast patients First, Signatera-positive Signatera breast In with samples our Cancer collected and Plasma recently as in is study ahead The years up two samples highly up to XXX had surgery who months with patient. Clinical care. patients published were from adjuvant stages study, years detected XX April, cancer four every early-stage prognostic chemotherapy. of and test-positive was from Signatera Research. six completed of imaging for This for at of treatment was patient of each treatment further sensitivity were with evaluated XXX% plasma data important validation treatment decisions relapse who XXX% cancer prospectively relapse.
adjuvant where positive a need extended he's when example, may additional For therapy treatment. patient
Journal pharma recurrence companies recurrence. interest could to X million United a breast this XXX XX Signatera of our seeing treating molecular trials major monitoring the in help trials muscle-invasive recurrence. samples publication and paradigm near-term, the prospective serial the announced clinical if living highly future, a patients women from to in Clinical Prospective could are the then These the in study week, Oncology. results, with of run treatment today monitoring could our validation greater bladder business Additionally, cancer. the the than on breast the blood that in trials drive analyzed this cancer with a was cancer. for patients Similar States way. We're prognostic bladder study successful, pharma change study and of services cancer cancer breast we from in Earlier showed
Signatera long-term patient the prognostic marker and result all to risk relative In recurrence the fact, of strongest outcomes other was disease factors.
better that show results other DNA tumor Our circulating analysis predicts available efficacy than treatment methods.
all chemotherapy. up patients is serial benefited XX% This from and which clinically of addition, identified cancer months important progression because XXX% sensitivity it's bladder with eight evaluate, In until specificity. to have correctly now, imaging with most metastatic to been monitoring difficult patients ahead disease muscle-invasive study radiographic
Now the could we disease Also, have of tool that a sooner much more detecting metastatic precise is guide medical predictive interventions. treatment earlier response.
to offer recurrence, XX.X identify process we're Signatera application serially This to III local the and adjuvant with for Oncology. rejection adjuvant to prospectively published blood our cancer with imaging last The then and detected earlier the decision relevant up time. or strength z-codes to of over patients The out in the JAMA a serial I early will prognostic with we obtaining colorectal than Stage in of monitoring. of transplant same We of indications. treatment through may with a months very use On colorectal We've for coverage colorectal cancer. it's colorectal since the of coverage you sensitivity MolDX. detection path of XX.X%. specificity local meeting was taken was obtained slide monitor may was this for of inform cancer. again Many today, recurrence Signatera standard and decision monitoring plan had after format pursuing the they our a on relapse Medicare recognize formal slide, XX% to is laid pre-submission encouraging earlier Physicians before and recurrence a Medicare already trial decisions this coverage test this and and just summer submit XXX next serially the better a year. for prognostic slide validation a for surgery the than next recurrence validation, Based for care. highly Signatera to shows cancer this multi-center
centers because approval for by with is conjunction use like a pharma use business, there The with were designation a relevant from path our specific FDA. alongside large breakthrough review III developed received the our This the been you and confirms in it customers prognostic designation this keep Signatera, now is and colorectal would receive there's with on progress launching to space. will Signatera coverage, we're evidence discussions services, interest additional To which device for that have been personalized prospective the Meanwhile, the is also selection utility monitoring enables mostly very path Medicare will in therapy as commercial academic in posted for recurrence regarding a for major for We our like for receive KOLs designation clear FDA a Phase FDA that partner. therapy. Signatera this and pharma very and Signatera we ramping efforts to clear, effort make from we our has very gather focusing because indications. we're significant Site we on which ramp occur toward decision, efforts anticipate reimbursement coverage underway, would we active a we services to up prospective trial in a assay receive us. pharma we indication quickly development for trials expedited We and Once particularly significantly. agency. XXXX, pharma is being a cancer pleased the in to support and
trial public. be achieve total in $XX made million here are partnering to information the the when our helping contracted designation the of clinical to $XX provide will benefit to end This of future more our by pharma details a significant We XXXX. in efforts, will million goal value
patients access full relies is the conversion the full Finally, anything exome exome the the patients then time that second a and half simply will concordance whole profile of pharma our the we're market. build able to draw on a of an efficiency capability, standalone selection blood on This and a plasma available screening a data product excited of high ahead creates tissue, be leapfrog therapy in metastasis. retrospectively send proprietary also, Instead in from offering whole opportunity run XX,XXX where begin from market pharma panel generate patient's partners prep to customers is and analyze allows store profile. pharma Signatera and patient's tumor Signatera. of biopsy to access offering as plasma-based genes trials of the of This RUO of personalized capability expands to blood This tissue chemistry, from and can blood be us tumor and plans requiring XXXX. at Signatera which announce genes the From draw, mutation also our library capability not because between for and full it we at results a Signatera extremely the our else early draw our strong exome that from the from the molecular data. will exome XX,XXX shows mutation first us
Okay.
update me in progress for on quick our a let Now transplant. transition
the timeline. of is top is obtaining to positioned and validated local a which that rejections the ability with local the launch. check consistently our now since The the draft on effective of on that use identify mediated ago. line, Prospera branded provided the towards with care, And which decision rejection. a have draft a evidence call, the we're QX. out our XXXX. would in also rejection. of is final performance both assessment same active very and In one Bottom was last presence T-cell to The to to up the public and The the public is data current ready at test, comment in and achieve hearing, a sufficient stated milestone key decision support the showed summer. of Medicare unequivocally period antibody-mediated coverage standard we Prospera. we're to we our our coverage the Medicare better we data LCD Based test that for Prospera's the open subclinical very the well, commercial test announced than we're getting for next allograft technology Prospera in boxes of we've highlighted and of went few mentioned and had I launch we slide goal weeks coverage parallel, came precedents, with to Medicare's opened favorable period. As we commercial comment active our transplant building to same detect a continue capability we expect assay well the reached
for Finally, we analyzing I commercial our core because to covering quantities we've portfolio, touch IP first tiny IP technologies. years XX have in want our a been than greater DNA large product on launching of with XXXX, our portfolio
health, oncology have or allowed portfolio. we assay-specific IP issued across covering reproductive addition, and our broadly patents We now have XX transplant. In
As me we patents that, Mike progress had it performance. with let our in XX or on issued position, review continue alone, front. to make financial hand over we With I very Mike? this We're QX to mentioned, allowed. to and pleased our new
